PD-Rx Pharmaceuticals, Inc.
PDRX
Other OTC3.35
USD
- -
- -
ISIN
US6932981011
CUSIP
693298101
Return %
Stock
S&P500
1Y
39.00
23.08
3Y
-44.17
67.59
5Y
17.54
74.74
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Robert D. Holsey
- Full Time Employees
- 28
- Sector
- Healthcare
- Industry
- Medical - Distribution
- Address
- 727 North Ann Arbor Oklahoma City OK United States of America 73127
- IPO Date
- Oct 15, 2003
- Website
- pdrx.com
- Similar Companies
- Business
- PD-Rx Pharmaceuticals, Inc. engages in the pharmaceutical services industry primarily providing pharmaceutical products and prepackaged medications to healthcare professionals. Founded in 1987 and headquartered in Oklahoma City, Oklahoma, the company operates as a licensed FDA manufacturer and packager, specializing in the repackaging and distribution of a broad array of pharmaceutical products including controlled substances, brand and generic drugs, and proprietary, specialty formulations. Its product offerings include in-office physician dispensing systems, over-the-counter medications, and a range of pharmaceutical management strategies aimed at improving healthcare network efficiency and patient care. PD-Rx emphasizes cost containment tools and patient compliance enhancement through its distribution and repackaging services, serving governmental, commercial, and point-of-care pharmaceutical segments across the United States. The company maintains a 100% pedigreed supply chain ensuring direct sourcing from manufacturers and authorized wholesalers, supported by regulatory compliance such as serialization under federal laws for prescription drug traceability. Recent strategic advances include completion of compliance with the Drug Supply Chain Security Act as of 2018, enhancing their ability to provide rapid product recall notifications and secure tracking. In the last 1-2 years, PD-Rx has focused on strengthening its operational capabilities and pharmaceutical personnel while reducing administrative expenses, reflecting an emphasis on maintaining quality customer service and operational integrity despite fluctuating revenues. Additionally, the company completed the repurchase of its outstanding preferred "C" shares, consolidating its equity structure. PD-Rx continues to grow its sales division and expand its pharmaceutical repackaging capacity, targeting healthcare providers looking for competitive pricing and streamlined medication access to improve treatment adherence and healthcare outcomes. It also provides specialized formularies for professional organizations and invests in developing systems that integrate with healthcare networks to offer comprehensive pharmaceutical services. The company’s ongoing business strategy centers on innovation in repackaging technology and expanding its portfolio of prepackaged medications, reinforcing its presence in the pharmaceutical services market. Overall, PD-Rx Pharmaceuticals offers a comprehensive range of pharmaceutical products and repackaging services, supported by regulatory compliance and strategic operational improvements aimed at healthcare market growth and improved patient service delivery. The company operates within the specialty pharmaceutical segment with a strong focus on controlled substance management, branded and generic drug distribution, and customer-centric service models across the U.S. healthcare market. The company’s headquarters remain in Oklahoma City with operational coverage primarily in the United States, leveraging partnerships and compliance frameworks to support healthcare providers with end-to-end pharmaceutical solutions and innovative dispensing methodologies. Recent operational refinements and financial maneuvers such as share repurchases reflect PD-Rx’s commitment to maintaining financial stability and enhancing shareholder value while navigating a competitive industry landscape.